Literature DB >> 1687082

Rift Valley fever on the east coast of Madagascar.

J Morvan1, J F Saluzzo, D Fontenille, P E Rollin, P Coulanges.   

Abstract

In March 1990, a Rift Valley fever virus (RVFV) outbreak was suspected in the district of Fenerive on the east coast of Madagascar after an abnormally high incidence of abortions and disease in livestock. Sera from humans and cattle were tested for RVFV antibodies by immunofluorescence assay (IFA) and ELISA-IgM capture. Sera and mosquitoes collected in the same area were tested for virus isolation by tissue culture and suckling mouse intracerebral inoculation, and for antigen detection by an ELISA antigen capture assay. Among cattle from the area, RVFV antibody prevalence was 58.6% by IFA and 29.6% by ELISA-IgM. In contrast, human populations in the same area had a lower RVFV antibody prevalence, with 8.01% IFA and 5.4% IgM-positive sera. No RVFV antigen was detected and virus isolation was unsuccessful from the sera and mosquito pools tested. Different hypotheses concerning the emergence and diffusion of RVFV in this area and the occurrence of the outbreak are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687082     DOI: 10.1016/0923-2516(91)90070-j

Source DB:  PubMed          Journal:  Res Virol        ISSN: 0923-2516


  28 in total

1.  Genetic reassortment of Rift Valley fever virus in nature.

Authors:  A A Sall; P M Zanotto; O K Sene; H G Zeller; J P Digoutte; Y Thiongane; M Bouloy
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Genetic evidence for Rift Valley fever outbreaks in Madagascar resulting from virus introductions from the East African mainland rather than enzootic maintenance.

Authors:  Serena A Carroll; Jean-Marc Reynes; Marina L Khristova; Soa Fy Andriamandimby; Pierre E Rollin; Stuart T Nichol
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

Review 3.  A review of mosquitoes associated with Rift Valley fever virus in Madagascar.

Authors:  Luciano M Tantely; Sébastien Boyer; Didier Fontenille
Journal:  Am J Trop Med Hyg       Date:  2015-03-02       Impact factor: 2.345

4.  Apoptosis of hepatocytes caused by Punta Toro virus (Bunyaviridae: Phlebovirus) and its implication for Phlebovirus pathogenesis.

Authors:  Xiaohua Ding; Fangling Xu; Hongli Chen; Robert B Tesh; Shu-Yuan Xiao
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

Review 5.  Molecular biology and genetic diversity of Rift Valley fever virus.

Authors:  Tetsuro Ikegami
Journal:  Antiviral Res       Date:  2012-06-16       Impact factor: 5.970

6.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

7.  Rift Valley fever virus seroprevalence in human rural populations of Gabon.

Authors:  Xavier Pourrut; Dieudonné Nkoghé; Marc Souris; Christophe Paupy; Janusz Paweska; Cindy Padilla; Ghislain Moussavou; Eric M Leroy
Journal:  PLoS Negl Trop Dis       Date:  2010-07-27

8.  Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR.

Authors:  Tetsuro Ikegami; Krishna Narayanan; Sungyong Won; Wataru Kamitani; C J Peters; Shinji Makino
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

Review 9.  Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.

Authors:  Michele Bouloy; Ramon Flick
Journal:  Antiviral Res       Date:  2009-08-12       Impact factor: 5.970

10.  Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1.

Authors:  Brian B Gowen; Min-Hui Wong; Kie-Hoon Jung; Lawrence M Blatt; Robert W Sidwell
Journal:  Antiviral Res       Date:  2008-01-07       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.